Molecular Mechanisms of Sex Differences in Cancer

43 concepts41 papers3 proposals

Cancer is frequently described as a disease of universal cellular malfunction. Yet, across almost all non-reproductive organs, a striking pattern emerges: men and women experience vastly different rates of cancer incidence, progression, and treatment response. Historically, these disparities were often dismissed as downstream consequences of lifestyle differences, such as higher rates of smoking or alcohol consumption among men.

However, modern molecular oncology reveals that sexual dimorphism is deeply hardwired into the biology of tumors. These differences are driven by distinct sex-hormone receptor pathways, sex-biased genomic mutations, and fundamentally different immune microenvironments. Understanding why these mechanisms diverge is essential for moving past a "one-size-fits-all" approach to oncology.

Direct Hormonal Wiring of Oncogenic Pathways

The most direct way biological sex influences cancer is through the interaction between sex hormones and intracellular signaling cascades. Rather than acting merely as systemic background factors, sex hormones directly regulate genes that drive or suppress tumor development.

Consider hepatocellular carcinoma (HCC), a primary liver cancer that is significantly more prevalent in men. Hai Feng et al. identified the molecular bridge responsible for this bias: the androgen receptor (AR) directly binds to the promoter of the gene encoding Cell Cycle-Related Kinase (CCRK), upregulating its expression. This increase in CCRK triggers the oncogenic $\beta$-catenin signaling pathway, stimulating rapid cellular proliferation in male liver tissue.

This pathway does not operate in isolation; it integrates with metabolic stress. Hanyong Sun et al. demonstrated that obesity-induced inflammation feeds directly into this same CCRK circuitry, driving mTORC1-dependent metabolic changes and immune evasion in a distinctly male-biased manner.

[In Males]   Androgens ➔ Androgen Receptor ➔ Upregulated CCRK ➔ β-catenin Signaling ➔ HCC Proliferation
[In Females] Estrogen  ➔ Estrogen Receptor ➔ FOXA1/FOXA2 Activation ➔ Tumor-Suppressive Signaling

Conversely, the female hormonal environment often deploys protective mechanisms against these same pathways. In the liver, "pioneer" transcription factors like FOXA1 and FOXA2 physically open closed chromatin to facilitate estrogen receptor signaling, which actively suppresses malignant transformation (Na Liu et al.).

When these protective barriers are absent or bypassed, the clinical consequences shift dramatically. For example, while men are three times more likely to be diagnosed with bladder cancer, women face significantly worse survival rates once the disease becomes muscle-invasive (Keiichiro Mori et al.). This susceptibility is partly rooted in genetic variations within hormone-metabolizing pathways, such as the HSD3B gene family, which alter the local balance of sex steroids within bladder tissue (Ting Hu).

The Sex-Biased Tumor Genome

The influence of biological sex extends deep into the tumor genome of non-reproductive organs, altering mutation rates, driver gene selection, and the underlying processes of DNA damage. As demonstrated by the authors of a comprehensive pan-cancer analysis (Sex differences in oncogenic mutational processes), distinct mutational signatures are heavily skewed by sex across thousands of non-reproductive tumors.

This genomic divergence is vividly apparent in non-small cell lung cancer (NSCLC). Even as smoking rates decline symmetrically between sexes, lung cancer incidence is dropping more slowly in women than in men.

Robert Hsu et al. discovered that hormone receptor expression is nearly twice as prevalent in female NSCLC patients compared to males. Crucially, this hormonal status directly correlates with the presence of critical "driver" mutations, such as EGFR and KRAS. The female hormonal milieu appears to create a distinct selective pressure that favors or sustains specific oncogenic genomic alterations, independent of traditional risk factors like tobacco exposure.

Sex-Specific Immune Microenvironments

Perhaps the most profound insight into why tumors behave differently across sexes lies within the immune system. Tumors rely heavily on suppressing the host's immune response to survive and grow. However, the cellular mechanisms responsible for this suppression can be entirely different depending on whether the host is male or female.

In glioblastoma (GBM), an aggressive brain tumor, males suffer from significantly higher incidence and worse clinical outcomes. Defne Bayık et al. uncovered the cellular basis for this disparity by examining myeloid-derived suppressor cells (MDSCs)—immune cells recruited by tumors to blunt T-cell attacks.

The authors found that the GBM microenvironment recruits entirely different subsets of MDSCs based on sex:

  • In males, tumor growth is driven by intra-tumoral, proliferating monocytic MDSCs.
  • In females, tumor growth is driven by systemic granulocytic MDSCs.

This divergence has massive therapeutic implications. An immunotherapy designed to target or deplete monocytic MDSCs might successfully unlock the immune system to destroy a tumor in a male patient, yet fail completely in a female patient whose tumor relies on granulocytic suppression.

Clinical Disparities and Therapeutic Resistance

These molecular and cellular variations translate directly into clinical disparities and treatment resistance in the clinic. For instance, in bladder cancer, estrogen receptor-beta (ER$\beta$) signaling has been shown to actively induce resistance to cisplatin chemotherapy, with a significantly stronger association observed in female patients than in male patients (Takuro Goto et al.).

Furthermore, the temporal dynamics of cancer development vary by sex. Large-scale screening data analyzed by Zhen Yuan et al. demonstrates that men develop precancerous colorectal lesions significantly earlier and more frequently than women. This indicates that "one-size-fits-all" screening ages are inherently inefficient, as biological sex fundamentally alters the timeline of tissue transformation.

Finally, these sex-based differences do not exist in a vacuum; they intersect with genetic ancestry and race. In gastric cancer, researchers identified a complete "prognostic reversal" between demographic groups: while White female patients generally maintain a survival advantage over White male patients, the opposite occurs in Asian populations, where males exhibit superior survival driven by distinct, race-specific core gene networks (Differences in the prognosis of gastric cancer patients of different sexes and races and the molecular mechanisms involved).

By treating biological sex not as a confounding variable but as a core driver of oncogenic wiring, genomic selection, and immune architecture, oncology can begin to design truly personalized prevention and treatment strategies.

History & citationVersion 1 · 2026-10-04

Current · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_sexual_dimorphism_in_oncology_3376f0ed,
  title = {sexual dimorphism in oncology},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/sexual-dimorphism-in-oncology/rdr_3376f0ed38124344a158ec99205e6a28},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-21},
}

This exact version (version 1, frozen text):

@misc{lacuna_sexual_dimorphism_in_oncology_3376f0ed_v1,
  title = {sexual dimorphism in oncology},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/sexual-dimorphism-in-oncology/rdr_3376f0ed38124344a158ec99205e6a28/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-21},
}
About

These directions overlap with this one through shared papers.

See something wrong? Report a mistake